Wnts Enhance Neurotrophin-Induced Neuronal Differentiation in Adult Bone-Marrow-Derived Mesenchymal Stem Cells via Canonical and Noncanonical Signaling Pathways by Tsai, Hung-Li et al.
 
Wnts Enhance Neurotrophin-Induced Neuronal Differentiation in
Adult Bone-Marrow-Derived Mesenchymal Stem Cells via
Canonical and Noncanonical Signaling Pathways
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Tsai, Hung-Li, Wing-Ping Deng, Wen-Fu Thomas Lai, Wen-Ta
Chiu, Charn-Bing Yang, Yu-Hui Tsai, Shiaw-Min Hwang, and
Perry F. Renshaw. 2014. “Wnts Enhance Neurotrophin-Induced
Neuronal Differentiation in Adult Bone-Marrow-Derived
Mesenchymal Stem Cells via Canonical and Noncanonical
Signaling Pathways.” PLoS ONE 9 (8): e104937.
doi:10.1371/journal.pone.0104937.
http://dx.doi.org/10.1371/journal.pone.0104937.
Published Version doi:10.1371/journal.pone.0104937
Accessed February 16, 2015 11:27:36 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987388
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAWnts Enhance Neurotrophin-Induced Neuronal
Differentiation in Adult Bone-Marrow-Derived
Mesenchymal Stem Cells via Canonical and Noncanonical
Signaling Pathways
Hung-Li Tsai
1, Wing-Ping Deng
2, Wen-Fu Thomas Lai
1,3,4,5*, Wen-Ta Chiu
5,6, Charn-Bing Yang
7,
Yu-Hui Tsai
1, Shiaw-Min Hwang
8, Perry F. Renshaw
9
1Graduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan, 2Graduate Institute of Biomedical Materials and Engineering, Taipei Medical University,
Taipei, Taiwan, 3Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan, 4McLean Imaging Center, McLean Hospital/Harvard Medical School,
Belmont, Massachusetts, United States of America, 5Center for Nano-Tissue Engineering and Image Research, Taipei Medical University Hospital, Taipei, Taiwan,
6Department of Neurosurgery, Taipei Medical University-Shuan-Ho Hospital, Taipei, Taiwan, 7Department of Orthopedics, Taipei County Hospital, Taipei, Taiwan,
8Bioresource Collection and Research Center, Food Industry Research and Development Institute, Hsinchu, Taiwan, 9Department of Psychiatry and The Brain Institute,
University of Utah, Salt Lake City, Utah, United States of America
Abstract
Wnts were previously shown to regulate the neurogenesis of neural stem or progenitor cells. Here, we explored the
underlying molecular mechanisms through which Wnt signaling regulates neurotrophins (NTs) in the NT-induced neuronal
differentiation of human mesenchymal stem cells (hMSCs). NTs can increase the expression of Wnt1 and Wnt7a in hMSCs.
However, only Wnt7a enables the expression of synapsin-1, a synaptic marker in mature neurons, to be induced and triggers
the formation of cholinergic and dopaminergic neurons. Human recombinant (hr)Wnt7a and general neuron makers were
positively correlated in a dose- and time-dependent manner. In addition, the expression of synaptic markers and neurites
was induced by Wnt7a and lithium, a glycogen synthase kinase-3b inhibitor, in the NT-induced hMSCs via the canonical/b-
catenin pathway, but was inhibited by Wnt inhibitors and frizzled-5 (Frz5) blocking antibodies. In addition, hrWnt7a
triggered the formation of cholinergic and dopaminergic neurons via the non-canonical/c-jun N-terminal kinase (JNK)
pathway, and the formation of these neurons was inhibited by a JNK inhibitor and Frz9 blocking antibodies. In conclusion,
hrWnt7a enhances the synthesis of synapse and facilitates neuronal differentiation in hMSCS through various Frz receptors.
These mechanisms may be employed widely in the transdifferentiation of other adult stem cells.
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Introduction
Cells with neuronal characteristics appear to be generated in
vitro from adult stem cells of putative mesodermal origin and can
be isolated from various connective tissues, including bone
marrow, umbilical cord blood, dermis, and adipose tissues
[1,2,3,4]. However, attempts to cause the transdifferentiation of
adult bone marrow-derived cells into neural lineages in vivo have
produced varied results. Some results showed the integration and
differentiation of these cells in the brain [5], whereas others
showed that the few cells capable of being engrafted into nervous
tissues fused with endogenous cells.
Exogenic or allogenic progenitor cells are clinically required to
serve as seeds of cellular repair for neural lesions. Among such
candidates, adult bone marrow-derived mesenchymal stem cells
(MSCs) deserve special attention because bone marrow harvesting
is associated with fewer ethical debates than are embryonic cell
sources. MSCs are multipotent stem cells that show osteogenic,
chondrogenic, and adipogenic capacities in appropriate environ-
ments [6]. In addition, immunosuppression by MSCs has been
observed in vitro and in vivo [7,8]; thus, MSCs exhibit potential
for clinical application. Previous studies demonstrated that either
animal [2,9,10,11] or human (h)MSCs [10,11] can transdiffer-
entiate into neuron-like cells that show neuronal markers such as
NeuN, nestin, microtubule-associated protein-2 (MAP2), neuron-
specific enolase (NSE), and neurofilament M (NFM). More
recently, synaptophysin (SYP), a marker of neurites, was observed
in rat MSCs in vitro [2]. The trigger for neuronal differentiation in
previous studies was cytokines, including brain-derived neuro-
trophic factor (BDNF), nerve growth factor-b (NGF), neurotrophin
(NT), fibroblast growth factor (FGF), retinoic acid (RA), and sonic
hedgehog (Shh), or chemical reagents such as b-mercaptoethanol
(BME), butylated hydroxyanisole (BHA), and dimethyl sulfoxide
(DMSO). However, no neurite marker has been reported in
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for neuronal regeneration remains poorly understood.
Wnt plays an essential role in neuronal initiation and
maturation in embryonic development. 19 secreted Wnt proteins
have been found in humans and are categorized into 12 families.
In the canonical pathway, Wnt ligands interact with Frizzled (Frz)
receptors and co-receptors, low-density lipoprotein receptor-
related protein (LRP)5/6, resulting in inhibition of glycogen
synthase kinase (GSK)-3b. This leads to b-catenin accumulation in
the cytoplasm and nuclear translocation. In nuclei, b-catenin
associates with the T-cell factor (TCF) and lymphoid enhancer
factor (LEF) to induce transcription of target genes [12]. Other
than the canonical/b-catenin pathway, Wnts also activate the non-
canonical/c-Jun N-terminal kinase (JNK) pathway [13,14] or the
non-canonical/calcium pathway to control cell behaviors [15,16].
The canonical Wnt pathway was reported to trigger differentiation
in neural progenitors in mice [17,18]. Wnt3 stimulates axon
branching and extends the growth cone size in proprioceptive
NT3-responsive sensory neurons [19]. Wnt7a promotes the
neurogenesis of cortical neural precursor cells [20] and synapto-
genesis in cerebellar and hippocampal neurons in animals [21]. In
b-catenin-independent Wnt signaling, Wnt7b activates signaling
through disheveled (Dvl), Rac, and JNK in immature hippocam-
pal neurons which show enhanced number and length of dendritic
branching [22].
Attempts were made to understand Wnt regulation of osteo-
genesis or adipogenesis using hMSCs [23]. In addition, canonical
Wnt was shown to augment the invasion and proliferation of
hMSCs [24]. However, the effects of canonical or non-canonical
Wnt signaling in neurogenic hMSCs are still little understood.
The goal of this study was to determine whether Wnt proteins
can enhance neurotrophin’s effect on neuronal differentiation of
hMSCs, defining the pathways of signaling into neurite pheno-
types and specific neuron types. Neurite formation and determi-
nation of specific neurons were examined by mRNA expression
and immunocytochemistry. We conclusively demonstrated en-
hancement of neuronal differentiation in neurotrophin-induced
hMSCs after cultivation with Wnts. Canonical and non-canonical
Wnt signaling via varied receptors facilitated transdifferentiation
into neuro-ectodermal lineages.
Materials and Methods
Ethics Statement
The protocols and informed consent form for bone marrow
hMSC isolation were approved by the Taipei Medical University
Joint Institutional Review Board (TMUH-03-08-12). The speci-
men donor was provided with an IRB-approved formal consent
form describing sufficient information for that person to make an
informed decision about his/her participation in this study. The
formal consent form was signed by the subject before specimen
collection.
Isolation and cultivation of hMSCs
Bone marrow samples were collected from five consenting
patients (age: 50–70) without endocrine disease in the Orthopedic
Section of Taipei Medical University Hospital (Taipei, Taiwan).
hMSCs were obtained using gradient centrifugation. Diluted
samples were placed on Percoll gradients (1.073 g/mL) (GE
Healthcare). Next, samples were fractionated using centrifugation,
and the MSC-enriched interface layer was collected. Isolated
hMSCs were mixed with hMSCs that were supplied by Cambrex,
and both types of hMSCs were cultured in 10-cm dishes using
Dulbecco’s modified Eagle’s medium with low glucose (DMEM/
LG) (Invitrogen), 10% fetal bovine serum (FBS) (Invitrogen), and a
1% penicillin-streptomycin mixture (Invitrogen). These mixtures
were cultured at 37uC in a humidified atmosphere with 5% CO2.
The medium was refreshed three times per week, and cells were
subcultured to confluence. All experiments were performed with
cells from passages 3–6.
Flow cytometric analysis
Confluent hMSCs (passages 3–6) were detached using a brief
trypsin treatment. The cells were fixed with 4% formaldehyde and
100% ice-cold methanol. Then, 5610
5 cells were incubated with
each mouse monoclonal primary antibody. These antibodies
included mouse phycoerythrin (PE)-labeled anti-CD14 (1:500;
clone M5E2, cat#555398, BD Biosciences), fluorescein isothiocy-
anate (FITC)-labeled anti-CD34 (1:500; clone 581/CD34,
cat#555821, BD Bioscience), PE-labeled anti-CD44 (1:500; clone
515, cat#550989, BD Bioscience), PE-labeled anti-CD73 (1:500;
clone AD2, cat#550257, BD Bioscience), FITC-labeled anti-
CD105 (1:500; clone SN6, cat#MCA1557F, AbD Serotec), PE-
labeled anti-CD166 (1:500; clone 3A6, cat#559263, BD Biosci-
ence), and anti-stro1 (1:500; clone STRO-1, cat#MAB1038,
R&D Systems). After incubation of the primary antibodies,
secondary FITC-labeled immunoglobulin G (IgG) antibodies
(1:100; Chemicon) were added to the group with unlabeled
primary antibodies. Following a final wash, cells were resuspended
in a 0.5 mL of buffer and analyzed on a Becton Dickinson FAC
Scalibur (Becton Dickinson). Mouse PE-labeled IgG1, FITC-
labeled IgG1, PE-labeled IgG2a, and IgM were used as negative
controls.
Neuronal transdifferentiation of hMSCs
To induce neuronal transdifferentiation, 10
5 hMSCs (passages
3–6) in 6-well plates were treated with NTs consisting of 1% FBS,
10 ng/mL BDNF (Chemicon), 20 ng/mL NGF (Chemicon), and
5 mM RA (Sigma) at 37uC in a humidified atmosphere with 5%
CO2, and the medium was refreshed three times per week. After 7
days of neurogenic differentiation, human recombinant (hr)Wnt1
(Peprotech), hrWnt3a (R&D Systems), hrWnt5a (R&D Systems),
hrWnt7a (R&D Systems), and LiCl (Sigma) were added at the
indicated concentrations (0.1,2 mg/mL or 1,4 mM) at various
times (0,48 h) for differentiation. In addition, hrWnt7a or LiCl in
DMEM/LG with 10% FBS was incorporated into hMSCs as the
control to confirm that Wnt signaling had no effect on
neurogenesis. Wnt7a signaling was inhibited by recombinant
human dickkopf-1 (DKK1) (R&D Systems), secreted frizzle-related
protein-4 (sFRP4) (R&D Systems), anti-human polyclonal Frz5
(cat#AF1617, R&D Systems), anti-mouse Frz9 monoclonal
antibodies (clone 291004, cat#MAB2440, R&D Systems), and
SP600125 (Santa Cruz). Furthermore, 24 h before the addition of
hrWnt7a, NT-induced hMSCs were treated with hrDKK1
(0.5 mg/mL), sFRP4 (2.5 mg/mL), anti-human Frz5 (1 mg/mL),
anti-mouse Frz9 antibodies (1 mg/mL), or SP600125 (15 mM).
Next, Wnt7a was incubated with the inhibitors in NT-induced
hMSCs for 48 h.
RNA isolation and quantitative reverse-transcription
polymerase chain reaction (qPCR)
Total RNA from the 10
5 hMSCs (passages 3–6) was extracted
using the TRIzol reagent (Invitrogen). cDNA synthesis was
performed using a SuperScript III system (Invitrogen). The qPCR
was carried out on a LightCycler 480 system (Roche Diagnostics)
using an LC-FastStart DNA Master SYBR Green I mix (Roche).
In addition, 5 mL of each cDNA was rapidly mixed with 1 mLo f
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Master SYBR Green I mix. The amplification profile was as
follows: enzyme activation at 95uC for 10 min; and annealing at
95uC for 10 s, 60uC for 5 s, and 72uC for 15 s. The specificity of
the PCR products was determined by a melting curve analysis.
The forward and reverse primers of the human genes were
designed using LightCycler Probe Design Software 2 (Roche), and
sequences are shown in table 1. Results are expressed relative to
the housekeeping gene, glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH).
Immunocytochemistry
hMSCs (passages 3–6) were fixed with 4% paraformaldehyde
for 10 min, and were permeabilized with 0.02% Triton X-100 for
10 min, followed by blocking with 5% FBS for 1 h and incubation
with primary antibodies for at least 1 h. The primary antibodies
were as follows: rabbit anti-MAP2 polyclonal antibodies (1:500;
cat#AB5622, Chemicon); rabbit anti-synapsin-1 (SYN1) poly-
clonal antibodies (1:500; cat#AB1543, Chemicon); mouse anti-
choline acetyltransferase (ChAT) monoclonal antibodies (1:500;
clone 1E6, cat#MAB305, Chemicon); and rabbit anti-dopamine
b-hydroxylase (DBH) polyclonal antibodies (1:500; cat#AB1585,
Chemicon); and mouse anti-b-catenin monoclonal antibodies
(1:500; clone 5H10, cat#MAB2081, Chemicon,). Cells were then
incubated for 1 h with secondary antibodies, goat anti-mouse
IgG:Dylight 488 (1:100; Serotec), or sheep anti-rabbit IgG:Dylight
649 (1:100; Serotec). The nuclear stain was 4’,6-diamidino-2-
phenylindole (DAPI) (Chemicon). Images were obtained using
fluorescent microscopy (Hamamatsu EM-CCD Camera C9100-
13). For b-catenin staining, cells with projections exceeding 30 mm
were considered neurite-positive cells. The cell area and neurite
length were calculated using ImageJ software. At least 1000 cells
from 10,15 viewing fields per group were used to calculate
percentages of cells. The human SH-SY5Y neuroblastoma cell line
was used as the positive control, and the human MG63
osteosarcoma cell line was used as the negative control. Mouse
IgG1 antibodies (Chemicon) were used as the isotype control. All
control results are shown in Figure S1.
Western blotting
After treatment, hMSCs (passages 3–6) were trypsinized and
dissolved in the M-PER Mammalian Protein Extraction Reagent
(Thermo Scientific), and then centrifuged for 15 min at
12,000 rpm and 4uC. The upper fluid, containing total protein,
was extracted. The extracted protein was denatured for 5 min at
95uC and loaded on a 10% SDS–PAGE gel. After electrophoresis,
denatured proteins were transferred onto polyvinylidene fluoride
membranes (Amersham Biosciences). The membrane was blocked
for 30 min in tris-buffered saline with 0.05% Tween-20 (TBS-T)
containing 5% bovine serum albumin and incubated overnight
with primary antibodies in TBS-T containing 2% nonfat milk.
The peroxidase-conjugated affinpure anti-mouse or anti-rabbit
IgG (Jackson ImmunoResearch) was added for 1 h. Bands were
visualized on film (Hyperfilm ECL, Amersham Pharmacia) by
using the ECL Plus kit (Amersham Pharmacia). The primary
antibodies were rabbit anti-MAP2 polyclonal antibodies (1:1000;
cat#AB5622, Chemicon); rabbit anti-SYN1 polyclonal antibodies
(1:1000; cat#AB1543, Chemicon); mouse anti-ChAT monoclonal
antibodies (1:1000; clone 1E6, cat#MAB305, Chemicon); rabbit
anti-DBH polyclonal antibodies (1:1000; cat#AB1585, Chemi-
con); and rabbit anti-GAPDH polyclonal antibodies (1:10000;
cat#ABS16, Chemicon). Electrophoresis and transfer materials
were purchased from Bio-Rad.
Statistical analysis
Data are presented as mean values 6 SD of all experiments or a
representative result of three or more experiments. Quantitative
data were analyzed using SigmaPlot 9.0 or SPSS software by
conducting either the Student’s t test or a one-way ANOVA. A
Table 1. Primers for the qPCR.
Gene Sequence (forward; reverse) Product length
GAPDH (glyceraldehyde 3-phosphate
dehydrogenase)
59-CGACCACTTTGTCAAGCTCA-39 59-AGGGGTCTACATGGCAACTG-39 228
MAP2 (microtubule-associated protein 2) 59-TTGGTGCCGAGTGAGAAGAA-39 59-GGTCTGGCAGTGGTTGGTTAA-39 100
Nestin 59-AAGAGAGCATAGAGGCAGTAA-39 59-GAGATTTCAGTGTTTCCAGGT-39 93
Neurotublin (neuron-specific class III beta-tubulin) 59-CTCTTCTCACAAGTACGTGC-39 59-CCTGAAGAGATGTCCAAAGG-39 97
SYTG (synaptotagmins 1) 59-TATTTGAGGAAGCAACTGAACAGG-39 59-CACACACACACACACGGA-39 87
SYN (synapsin 1) 59-GCAAACTCCACCCATCTT-39 59-ACACAGACACCACAGCA-39 85
BSN (bassoon) 59-CCAAGGGTTTGCCAGATTGTA-39 59-GCTCTTGAAGAAATGAAGAGAGGTA-39 115
ChAT (choline acetyltransferase) 59-CCGGTTTGTCCTCTCCACTA-39 59-ATACCCATTTGGGACCACAG-39 82
DBH (dopamine beta-hydroxylase) 59-ATATCTCCGCCTGGAAGTTCA-39 59-TGTGTAGTACAAGCGGATGC-39 85
DVL (dishevelled 1) 59-CCACCCTGAACCTCAACAGT-39 59-CCTTCACTCTGCTGACTCCC-39 202
LEF (lymphoid enhancer-binding factor 1) 59-AAGGAGCAGGAGCCAAA-39 59-CTCAGCAACGACATTCGC-39 93
Wnt1 59-AACAGCGGCGTCTGATAC-39 59-GCGGAGGTGATAGCGAAG-39 199
Wnt3a 59-ATGAACCGCCACAACAAC-39 59-TTCTCCACCACCATCTCC-39 188
Wnt5a 59-GGGAGGTTGGCTTGAACATA-39 59-GAATGGCACGCAATTACCTT-39 141
Wnt7a 59-TGGCTTCTCCTCAGTGGTAG-39 59-CCTTCTCCTATGACGATGATGG-39 123
Wnt7b 59-TATCCCAGAGAGCAAAGTG-39 59-TGTGTTAGTGCCGAGAATC-39 204
doi:10.1371/journal.pone.0104937.t001
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Results
Characterization of bone-marrow-derived human
mesenchymal stem cells
The human bone-marrow-derived MSCs were characterized
using cell surface markers by performing flow cytometric
analysis (Fig. 1A). The MSCs tested positively for hMSC-specific
cell type markers, such as CD44, CD73, CD105, CD166, and
Stro1, as indicated in previous reports [6,25], and the
hematopoietic-stem-cell (HSC)-specific cell type markers CD14
and CD34 were negative in isolated hMSCs after 3 passages
[6,25]. The data revealed that none of the isolated cells were
HSCs or blood cells.
Expression profile of Wnt family genes during the
neuronal differentiation of human mesenchymal stem
cells
We confirmed the neuronal induction of NTs by using a
neuronal marker, MAP2, in the cultivation system (Fig. 1B), and
then determined the roles of Wnts during hMSC neurogenesis. A
qPCR was used to examine the mRNA expression of Wnt1,
Wnt3a, Wnt5a, Wnt7a, and Wnt7b in hMSCs cultured with NTs.
Canonical Wnt3a and non-canonical Wnt5a exhibited sustained
expression with no significant changes during neuronal transdif-
ferentiation (Fig. 1C). NTs seemed not to control these 2 Wnt
genes in neurogenic hMSCs. Canonical Wnt1 exhibited relatively
low expression in both the untreated control and NT-induced
groups compared with the other 4 Wnt mRNAs at each time point
(Fig. 1C). The mRNA levels of Wnt7a and Wnt7b were not
detectable in untreated hMSCs, but were expressed significantly
following NT induction during 3 periods (Fig. 1C). The expression
Figure 1. Flow cytometric analysis and Wnt profiles of hMSCs by the induction of NTs. (A) Bone marrow-derived hMSCs were analyzed
following four cell passages. hMSCs were positive for CD44, CD73, CD105, CD166, and Stro-1, and negative for CD14 and CD34. The solid curves
indicate each type of antibody, and the filled curves indicate mouse IgG as the negative control. (B) mRNA levels of MAP2 were quantified on days 7,
14, and 21 during stimulation with NTs. NTs significantly increased MAP2 levels on days 14 and 21. Untreated hMSCs served as the control. (C) mRNA
levels of Wnt1, Wnt3a, Wnt5a, Wnt7a, and Wnt7b were quantified on days 7, 14, and 21 during stimulation with NTs. NTs increased the expression of
Wnt1 and induced expressions of Wnt7a and Wnt7b.*p,0.05, ** p,0.01 (i.e., treated vs. control in the Wnt1, Wnt3a, and Wnt5a groups; NTs at 14
and 21 days vs. NTs at 7 days in the Wnt7a and Wnt7b groups). Data are presented as the mean 6 SD of one triplicate experiment that was
representative of three independent experiments. * p,0.05, ** p,0.01 (i.e., treated vs. control). ND, not determined.
doi:10.1371/journal.pone.0104937.g001
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results indicated that Wnt7a and Wnt7b play roles in the neuronal
differentiation of hMSCs.
Neurogenic effects of various Wnt treatments on
neurotrophin-induced human mesenchymal stem cells
Previous studies have reported that Wnts induce osteogenic
differentiation [26,27,28]; therefore, to avoid osteogenic activation
by Wnts, NTs were treated before Wnts were added to the culture
medium. To determine which Wnt triggers the neurogenic
differentiation of hMSCs, we added 2 mg/mL of hrWnt to hMSCs
for 2 days after 1 week of treatment with NTs. For the general
neuron marker, MAP2, all 4 Wnts induced approximately 2-fold
increases compared with the NT group (Fig. 2A). No statistically
significant changes in MAP2 expression were observed among all
4 Wnt groups. To determine the function of synapses in neuronal
differentiation, we examined the mRNA expression of SYN1,
which was associated with the cytoplasmic surfaces of synaptic
vesicles. qPCR data indicated that, when the cells were treated
only with NTs, the expression of the synaptic marker SYN1 did
not change in cells (Fig. 2A). Wnt7a increased the expression of
SYN1 3.7-fold and that of Wnt1 and Wnt3a 2.4- and 2.7-fold,
respectively. However, Wnt5a did not significantly change SYN1
expression compared with the NT only group (Fig. 2A).
To determine the differentiation of the hMSCs into specific
neurons, we evaluated a marker of cholinergic neurons, ChAT,
and a marker of dopaminergic neurons, DBH. Wnt3a, Wnt5a,
and Wnt7a increased the mRNA levels of ChAT approximately
1.5-fold, 8-fold, and 5-fold, respectively, except Wnt1 exerted no
effect on ChAT (Fig. 2B). Wnt5a and Wnt7a increased the mRNA
levels of DBH approximately 1.2-fold and 2-fold, respectively;
however, neither Wnt1 nor Wnt3a affected mRNA levels of DBH
(Fig. 2B). These data indicated that Wnt7a can facilitate the results
of neuronal differentiation in MSCs.
To determine the correlation of neuronal genes with Wnt
signaling activity, we examined the expression of LEF1,a
downstream target gene of canonical Wnt signaling [29] in the
canonical Wnt/b-catenin pathway. Wnt1, Wnt3a, and Wnt7a
markedly increased LEF1 expression. As we hypothesized, a
positive correlation of SYN1 expression with the activation of the
canonical Wnt/b-catenin pathway was observed (Fig. 2A). In
contrast, LEF1 exhibited no or minimal correlation with ChAT or
DBH, which are markers of specific neuronal gene expression
(Fig. 2B). These results suggested that more than one non-
canonical signaling pathway controls specific neuronal gene
expression.
Figures 1 and 2 show that NT-induced Wnt1 and Wnt7a can
trigger MAP2 expression in NT-treated hMSCs. Wnt1 exhibited
no effects on specific neuronal differentiation, whereas Wnt7a
enabled extensive triggering of neuronal differentiation in hMSCs.
Therefore, we used Wnt7a in subsequent experiments.
Dose- and time-dependent effects of Wnt7a treatment in
neurotrophin-induced human mesenchymal stem cells
To investigate the effects of Wnt7a on the neurogenesis of
hMSCs, we added human recombinant Wnt7a to NT-induced
hMSCs and subsequently analyzed the mRNA expression of
neuronal markers. The expression of nestin (a neural progenitor
marker), neurotubulin (a neuron-specific b3 tubulin), and MAP2
(a general neuron marker) increased in a Wnt7a-dose- and time-
dependent manner in the NT-induced cells (Fig. 3A, B). In
addition, Wnt7a exhibited dose- and time-dependent positive
effects on expression of the glial fibrillary acidic protein (an
astrocyte marker) and myelin basic protein (an oligodendrocyte
marker) in NT-treated hMSCs (Fig. S2).
DVL, a cytoplasmic phosphoprotein, was reported to act
directly downstream of frizzled receptors. Expression of DVL1
exhibited a strong correlation with canonical Wnt signaling
activation [30]. We examined whether Wnt7a-upregulated neu-
rogenic differentiation involves canonical Wnt signaling. DVL1
expression significantly increased in Wnt7a-induced hMSCs
(Fig. 3A, B), indicating that Wnt7a enhances NT-induced
neurogenesis in hMSCs through the canonical Wnt pathway.
Expression of synapse markers is stimulated by Wnt7a in
neurogenic human mesenchymal stem cells through the
canonical Wnt pathway
To determine whether Wnt7a triggers hMSCs to differentiate
into neuron-like cells, we examined the expression of synaptic
markers, namely SYN1, basson (BSN), and synaptotagmin
(SYTG), in NT-treated hMSCs. Treatment with either NTs for 9
days or Wnt7a for 2 days produced no effects on SYN1 expression
in hMSCs (Fig. 4A). By contrast, following 7 days of pretreatment
with NTs, hrWnt7a significantly increased SYN1 mRNA 4-fold
compared with the NT treatment alone (Fig. 4A). LEF1 exhibited
higher expression in the group treated with NTs and Wnt7a. In
addition, NTs and Wnt7a triggered increases in BSN (approxi-
mately 12-fold) and SYTG (approximately 2-fold) in a similar
manner.
Immunocytochemistry and immunoblotting were conducted to
confirm the results of qPCR analysis. We first observed b-catenin
accumulation in nuclei after 24 h of treatment with Wnt7a or
lithium. b-Catenin was colocalized with nuclear staining in
Wnt7a- and lithium-treated hMSCs, whereas b-catenin accumu-
lation was undetectable in the nuclei of the hMSC control group
(Fig. 5A). This observation indicated that Wnt activation occurs
via a canonical pathway. Immunocytochemistry and immuno-
blotting were conducted 7 days after the cells were treated with
NTs for 7 days. Immunoblotting revealed that Wnt7a and lithium
upregulated MAP2 and SYN1 expression; this result was
consistent with that obtained using qPCR (Fig. 5B). Immunocy-
tochemistry revealed that the NT group exhibited mild MAP2
expression (6%) but no SYN1 expression (Fig. 5C, D). By contrast,
when Wnt7a or lithium was added to the culture medium with
NTs for 7 days, hMSCs robustly expressed MAP2 (16.3% and
11.8%) and SYN1 (10.7% and 4.8%) (Fig. 5C, D). Morphological
changes were evaluated using cytoskeletal b-catenin staining to
quantitate the numbers of cell areas and neurite-positive cells. The
immunocytochemical evaluation revealed that Wnt7a and lithium
facilitated increases in neurite formation (5.4% and 2.8%) and
decreases in cell bodies in NT-treated hMSCs after 14 days of
treatment (Fig. 5D, E). The immunocytochemical evaluation
revealed that Wnt7a triggered NT-treated hMSCs to differentiate
into neuron-like cells through a canonical Wnt pathway.
Induction of synapsin-1 expression in neurogenic human
mesenchymal cells through the canonical Wnt pathway
using a glycogen synthase kinase 3b inhibitor
To activate and mimic the canonical Wnt/b-catenin pathway,
we used a GSK-3b inhibitor, lithium. The mRNA expression of
SYN1 induced by 1 and 4 mM LiCl and NTs was respectively
12.2% and 46.1% higher than those induced only by NTs
(Fig. 4B). LEF1 was activated in the lithium groups. This
demonstrated that canonical Wnt signaling stimulated neuron-
like cells generated by hMSCs.
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Wnt7a-treated human mesenchymal stem cells by Wnt
inhibitors and Wnt7a receptor antibodies
To determine whether SYN1 induction is dependent on Wnt7a
signaling in NT-treated hMSCs, we added Wnt7a inhibitors, the
DKK1, sFRP4, Frz5, and Frz9 antibodies, to NT/Wnt7a-treated
hMSCs. DKK1, a protein that interacts with LRP5/6, blocks the
canonical Wnt pathway. Decreases in SYN1 mRNA (12%) and
LEF1 levels (24%) occurred, as shown in Fig. 6A and 6B. sFRP,
composed of a cysteine-rich Wnt-binding domain similar to the
region in Frzs ligands, acts as a soluble antagonist for Wnt signals.
A previous study demonstrated that sFRP4 bound to Wnt7a and
inhibited canonical Wnt7a signaling in human endometrial cancer
Figure 2. Neurogenic effects from different Wnts in NT-induced hMSCs. (A) mRNA levels of MAP2, SYN1, and LEF1 were quantified after 48 h
of different Wnt treatments (2 mg/ml) in hMSCs that had been treated with NTs for 1 week. All Wnts promoted MAP2 expression, and Wnt7a induced
the highest SYN1 expression. Levels were normalized to those of NTs treatments (set to 1.0). Data are presented as the mean 6 SD of one triplicate
experiment that was representative of three independent experiments.
1 p,0.05,
10 p,0.01 (DMEM vs. all groups);
2 p,0.05,
20 p,0.01 (NTs vs. all
groups);
3 p,0.05,
30 p,0.01 (Wnt1 vs. all groups);
4 p,0.05,
40 p,0.01 (Wnt3a vs. all groups);
5 p,0.05,
50 p,0.01 (Wnt5a vs. all groups);
6 p,0.05,
60
p,0.01 (Wnt7a vs. all groups). (B) mRNA levels of ChAT, DBH, and LEF1 were quantified after 48 h of different Wnt treatments (2 mg/ml) in hMSCs that
had been treated with NTs for 1 week. Wnt1 had no effects on ChAT or DBH expressions, but Wnt7a significantly induced both genes. Levels were
normalized to those of NTs treatments (set to 1.0). Data are presented as the mean 6 SD of one triplicate experiment that was representative of three
independent experiments.
1 p,0.05,
10 p,0.01 (DMEM vs. all groups);
2 p,0.05,
20 p,0.01 (NTs vs. all groups);
3 p,0.05,
30 p,0.01 (Wnt1 vs. all
groups);
4 p,0.05,
40 p,0.01 (Wnt3a vs. all groups);
5 p,0.05,
50 p,0.01 (Wnt5a vs. all groups);
6 p,0.05,
60 p,0.01 (Wnt7a vs. all groups).
doi:10.1371/journal.pone.0104937.g002
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SYN1 (45%) and LEF1 (60%) was inhibited in NT/Wnt7a-
induced hMSCs (Fig. 6A, B). These results indicated that sFRP4
and DKK1 inhibited the activation of the canonical Wnt7a
pathway and suppressed the differentiation of neuron-like cell
generation by hMSCs. Recent studies have demonstrated that
Frz5 and Frz9 act as Wnt7a receptors [31,32]. Therefore, we used
Frz5 and Frz9 antibodies as Wnt7a inhibitors. After incubating
NT/Wnt7a-treated hMSCs with antibodies, SYN1 expression
decreased 81% and 43% in the Frz5 group and Frz9 group,
respectively, compared with the control group (Fig. 6A, B). In
addition, Frz5 (94%) and Frz9 (56%) antibodies suppressed LEF1
expression, implying that Frz5 is a primary receptor that binds to
Wnt7a, which activates the canonical Wnt pathway. These results
indicated that Wnt7a interacts with Frz5 and Frz9 through the
activation of the canonical Wnt pathway, controlling synapse
formation by neurogenic hMSCs.
Determination of specific neuron types by using Wnt7a
in neurotrophin-induced human mesenchymal stem cells
through the non-canonical/c-Jun N-terminal kinase
pathway
To examine whether Wnt7a signals trigger the differentiation of
NT-treated hMSCs into specific neuron-like cells, we analyzed
markers of cholinergic, dopaminergic, GABAergic, and seroto-
nergic neurons in NT-treated hMSCs after the cells were treated
with Wnt7a or lithium. Compared with the DMEM group, DBH
mRNA was expressed at similar levels in NT-induced cells,
whereas a 3-fold increase was observed after Wnt7a was added.
Moreover, compared with the DMEM group, ChAT, glutamate
decarboxylase-1 (GAD), and serotonin transporter (SERT) expres-
sion increased in the NT group, but treatment with Wnt7a and
NTs induced an 8-fold increase in ChAT expression (Figs. 7A and
S3). Treatment with lithium and NTs exerted no effect on the
expression of DBH, ChAT, GAD and SERT compared with NT
only group (Fig. 7A). Immunoblotting revealed features similar to
Figure 3. Dose- and time-dependent effects of Wnt7a in neurogenic hMSCs. mRNA levels of nestin, MAP2, neurotubulin, and DVL1 were
quantified after 48 h of Wnt7a treatment (0.1,1.5 mg/ml) in a dose-dependent study (A) and at various times (i.e., 6,48 h) after Wnt7a treatment
(2 mg/ml) in a time-dependent study (B). NTs combined with Wnt7a promoted expression of neuronal genes related to the canonical Wnt pathway in
time- and dose-dependent manners. Levels were normalized to those of NTs treatments (set to 1.0). Data are presented as the mean 6 SD of one
triplicate experiment that was representative of three independent experiments. * p,0.05, ** p,0.01 (NTs and Wnt7a vs. DMEM; NTs+Wnt7a vs. NTs).
doi:10.1371/journal.pone.0104937.g003
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and NT groups, Wnt7a-induced increases in the protein levels of
ChAT and DBH were greater than those induced by lithium
(Fig. 7B). Previous studies have demonstrated that Wnt7a can
trigger the canonical/b-catenin and JNK pathways [31,33]. To
determine whether Wnt7a triggers the non-canonical/JNK
pathway to activate the differentiation of specific neurons, we
added SP600125, a JNK inhibitor, and Wnt7a or lithium before
conducting qPCR analysis. The results indicated that SP600125
completely inhibited Wnt7a-induced ChAT and DBH expression
(Fig. 7A). However, SP600125 did not reduce Wnt7a-induced
MAP2 or SYN1 expression (Fig. 7C). These findings indicate that
Wnt7a induces the differentiation of specific neurons through the
non-canonical/JNK pathway in NT-treated hMSCs.
Immunostaining revealed that NT/Wnt7a treatment induced
12.3% and 8.8% increases in ChAT and DBH expression in
hMSCs; these results were consistent with those obtained in qPCR
analysis. By contrast, decreases in ChAT (2.3%) and DBH (0.9%)
were observed after SP600125 was added (Fig. 7D, E). In NT/
lithium-treated hMSCs, no significant changes compared with the
hMSCs treated only with NT were observed regardless of whether
SP600125 was added (Fig. 7D, E). Overall, these results indicated
that Wnt7a triggers immature neurons in hMSCs to differentiate
into specific neuron-like cells, including cholinergic and dopami-
nergic neurons. In summary, our results indicated that the
generation of neuron-like cells is triggered through both canonical
and non-canonical Wnt pathways.
We then examined whether Wnt inhibitors and Frz blocking
antibodies downregulate the non-canonical/JNK pathway. The
results indicated that sFRP4 and Frz9 antibodies significantly
lowered ChAT and DBH expression in Wnt7a-induced hMSCs
(Fig. 7F). sFRP4 inhibited ChAT expression by 40% and DBH
expression to 48%, and the Frz9 antibody significantly inhibited
ChAT expression to 79% and DBH expression to 84% (Fig. 7G).
DKK1 and the Frz5 antibody exerted mild inhibitory effects;
therefore, they do not seem to play a major role in the non-
canonical pathway (Fig. 7F, G). Collectively, these results indicat-
ed that Wnt7a activated the non-canonical/JNK pathway to
induce the differentiation of specific neurons through the Frz9
receptor, but sFRP4 inhibited this induction.
Discussion
Wnt signaling not only regulates embryonic development and
adult homeostasis but also controls several processes in adult stem
cells. Several previous studies have focused on regulatory
mechanisms among Wnts and osteogenesis [28], chondrogenesis
[34], adipogenesis [23], and myogenesis [35]. However, the
relationship between Wnts and neurogenesis in hMSCs is unclear.
Our results revealed that Wnt7a plays a crucial role in the
specification and maturation of neurons from hMSCs. In addition,
we proved that both the canonical and non-canonical Wnt
signaling pathways facilitate neurogenesis triggering in hMSCs.
Takako et al. reported that hrWnt1 and Wnt3 (400 ng/mL) in a
neural induction medium induced sensory neuron markers (Ngn1,
NeuroD, Brn3a, and P2X3) and a glutamatergic neuron marker
(GluR 1-4) in mouse MSCs via the canonical/b-catenin pathway
[36]. NTs significantly stimulated hMSCs to express Wnt1 and
Wnt7a. Both Wnts triggered more MAP2 and SYN1 expression
than did NT treatment alone. However, Wnt1 exerted no effects
on inducing the differentiation of cholinergic and dopaminergic
neurons. Moreover, Wnt7a did not stimulate hMSCs to express
the glutamatergic neuronal marker, glutamate dehydrogenase 1
(Fig. S3). Our results and those of Takako collectively indicate that
Wnts play crucial roles in controlling MSC neurogenesis via
canonical and non-canonical pathways.
Various methods trigger neurogenesis in hMSCs, including
chemical induction [37], gene transfection [38,39], and the use of
conditioned media from rodent brains [39]. However, these
methods are either limited in animal models or involve high risks.
Cytokine induction of hMSCs appears to be safer than chemical
induction or gene transfection in the human body. RA, BDNF,
Figure 4. Induction of synaptic markers by Wnt7a and lithium in NT-stimulated hMSCs. (A) Wnt7a groups were treated with Wnt7a (2 mg/
ml) for 2 days, and the NTs groups were treated with NTs for 9 days. After NTs treatment for 1 week, Wnt7a (2 mg/ml) was added to the NTs+Wnt7a
groups for 2 days. mRNA levels of LEF1, SYN1, BSN, and SYTG were examined in hMSCs, and levels were normalized to those in the NTs control (set to
1.0). Wnt7a induced mRNA expressions of SYN1, BSN, and SYTG in NT-stimulated hMSCs, and this induction was related to upregulation of LEF1. Data
are presented as the mean 6 SD of one triplicate experiment that was representative of three independent experiments. * p,0.05, ** p,0.01 (NTs
and Wnt7a vs. DMEM; NTs+Wnt7a vs. NTs). (B) LiCl groups were treated with LiCl (4 mM) for 2 days, and NTs groups were treated with NTs for 9 days.
After NTs treatment for 1 week, LiCl (1 or 4 mM) was added to the NTs+LiCl groups for 2 days, mRNA levels of SYN1 and LEF1 were examined in
hMSCs, and their levels were normalized to those in the DMEM control (set to 1.0). * p,0.05, ** p,0.01 (NTs and LiCl vs. DMEM; NTs+LiCl vs. NTs).
doi:10.1371/journal.pone.0104937.g004
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PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e104937Figure 5. Immunostaining and immunoblotting of NT-stimulated hMSCs with Wnt7a or lithium. (A) p4 NT-treated hMSCs were stained
with b-catenin (green). The NTs+Wnt7a groups were treated with NTs+Wnt7a for 24 h, and the NTs+lithium groups were treated with NTs+lithium for
24 h. 4,6-Diamidino-2-phenylindole (DAPI) (blue) was used as a counterstain. (B) p4 NT-treated hMSCs were immunoblotted with MAP2, SYN1, and
GAPDH. The NT group was treated with NTs for 14 days. The NTs+Wnt7a and NTs+lithium groups were treated with NTs for 7 days first, and then with
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[10]. We observed that NT/Wnt7a -treated hMSCs expressed
axonal markers, such as SYN1. Our protocol for the neuronal
differentiation of hMSCs is simple and feasible both in vitro and as
an animal model for generating human neurons. Our protocol
provides a new therapeutic opportunity for clinics.
Synaptic markers, such as SYN1, SYTG, BSN, synaptic vesicle
2 (SV2), and SYP, are markers of mature neurons. Cho et al.
demonstrated that SV2 and SYP are present following treatment
with RA and interleukin-1a for 10–12 days in hMSCs [40]. In
addition, Trzaska et al. [41] demonstrated that treatment with
Shh, FGF8, and bFGF for 12 days triggered hMSCs to become
SV2-positive cells. Our data are consistent with those of 2 previous
studies and revealed the quantitative effects of cytokines. The
expression of SYP mRNA was observed in RT-PCR analysis on
the fourteenth day after small-interference neuronal restrictive
silencing factor (NRSF) RNA was used [42]. Gene transfection
research has become more concerned with clinical application.
Our protocol for neuronal induction is more efficient and feasible
than other protocols. Our study clearly revealed that Wnt7a, after
BDNF, NGF, and RA induction, functions as a synaptic enhancer.
Tuli et al. reported that human bone-marrow-derived MSCs
incorporated with a chondrogenic factor, transforming growth
factor (TGF)-b, express Wnt7a mRNA [34]. Zhou et al.
demonstrated that TGF-b with lithium promoted chondrogenesis
and inhibited adipogenesis [34,43]. These results imply that
Wnt7a is a chondrogenic factor in human bone-marrow-derived
MSCs, although direct evidence is lacking. Our results indicated
that Wnt7a facilitates neuronal differentiation in human bone-
marrow-derived MSCs.
The Wnt family is divided into 2 groups based on the signaling
pathways that they activate. Canonical Wnts, such as Wnt1 and
Wnt3a, activate the canonical/b-catenin pathway, whereas non-
canonical Wnts modulate b-catenin-independent signaling path-
ways, such as the Wnt/calcium and Wnt/JNK pathways [12]. In
previous studies, synaptic formation and neurotransmitter releases
in the brain have been controlled using Wnt7a through the Wnt
canonical pathway [44,45]. Wnt7b activates the canonical
pathway to connect olfactory receptor neuron axons with the
forebrain [46]. Furthermore, Wnt7b regulates dendritic develop-
ment in hippocampal neurons through the Dvl, Rac, and JNK
pathways [21]. In endometrial cancer cells, Wnt7a interacts with
various receptors to stimulate the canonical Wnt pathway and
Wnt/JNK pathway [31]. Our data indicated that both Wnt7a and
lithium controlled SYN1 expression through the canonical Wnt
pathway. However, Wnt7a, but not lithium, controlled neuronal
determination in NT-induced hMSCs, and we used SP600125 to
show that neuron-type differentiation is regulated by a Wnt-
independent pathway. Our results revealed that Wnt7a triggered
canonical Wnt signaling to differentiate general neurons and
activated non-canonical Wnt signaling to transform hMSCs into
cholinergic and dopaminergic neurons. Furthermore, we demon-
strated that Wnt7a used different Frz receptors to determine
activation of neuronal genes through a canonical or non-canonical
pathway. Frz-determined activation is consistent with the findings
of previous studies [31,33].
Gene transfer is a method of converting hMSCs into mature
neurons. In 2004, Dezawa et al. transfected hMSCs with the
Notch intracellular domain and subsequently treated the hMSCs
with bFGF, forskolin, and ciliary neurotrophic factors in media
[38]. However, this protocol can generate only neural progenitor-
NTs+Wnt7a or lithium for 7 days. DMEM groups served as controls. (C) p4 NT-treated hMSCs were stained with MAP2 (red), SYN1 (red), and b-catenin
(green). NTs groups were treated with NTs for 14 days. The NTs+Wnt7a and NTs+lithium groups were treated with NTs for 7 days first, and then NTs+
Wnt7a or lithium for 7 days. DAPI (blue) was used as a counterstain. DMEM groups served as the control. The white bar represents 50 mm. (D)
Percentages of MAP2-positive cells, SYN1-positive cells, and neurite-positive cells among all DAPI-positive cells. All data are presented as the mean 6
SD. * p,0.05, ** p,0.01 (all vs. NTs). (E) Cell areas were calculated by b-catenin-positive cells from (B).
doi:10.1371/journal.pone.0104937.g005
Figure 6. Inhibitory effects of Wnt inhibitors and blocking antibodies in Wnt7a-induced synapsin expression. (A) As described in
"Materials and Methods", mRNA levels of SYN1 and LEF1 were examined by a qPCR. sFRP4 showed significant inhibition of SYN1 expression, and Frz5
blocking antibodies greatly inhibited gene expressions. Levels were normalized to those in NTs groups (set to 1.0). * p,0.05, ** p,0.01 (NTs+Wnt7a
vs. all groups). (B) Percentages of inhibition calculated from (A). Data are presented as the mean 6 SD of one triplicate experiment that was
representative of three independent experiments.
doi:10.1371/journal.pone.0104937.g006
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PLOS ONE | www.plosone.org 10 August 2014 | Volume 9 | Issue 8 | e104937Figure 7. Neuronal specification by the non-canonical Wnt7a pathway in NT-induced hMSCs. (A) mRNA levels of ChAT and DBH were
examined in NT-induced hMSCs, and SP600125 (15 mM) and Wnt7a (2 mg/ml) or LiCl (4 mM) were added to NT-induced hMSCs at the same time.
Levels were normalized to those in the NTs control (set to 1.0). Wnt7a, but not lithium, stimulated mRNA levels in NT-induced hMSCs, and SP600125
totally inhibited Wnt7a-induced ChAT and DBH expressions. Data are presented as the mean 6 SD of one triplicate experiment that was
representative of the three independent experiments. * p,0.05, ** p,0.01 (all vs. NTs).
# p,0.05,
## p,0.01 (all vs. NTs+Wnt7a+SP600125).
+ p,
0.05,
++ p,0.01 (all vs. NTs+LiCl+SP600125). (B) p4 NT-treated hMSCs were immunoblotted with ChAT, DBH, and GAPDH. The NT groups were treated
with NTs for 14 days. The NTs+Wnt7a and NTs+lithium groups were treated with NTs for 7 days first, and then with NTs+Wnt7a or lithium for 7 days.
DMEM groups served as controls. (C) Expression levels of MAP2 and SYN1 in NT-induced hMSCs with SP600125/Wnt7a or SP600125/LiCl are shown.
SP600125 had no effect in MAP2 or SYN1 expression. Levels were normalized to those in NTs groups (set to 1.0). * p,0.05, ** p,0.01 (NTs vs. all
groups).
# p,0.05,
## p,0.01 (all vs. NTs+Wnt7a+SP600125).
+ p,0.05,
++ p,0.01 (all vs. NTs+LiCl+SP600125). (D) p4 NT-treated hMSCs were stained
with ChAT (green) and DBH (red). NTs groups were treated with NTs for 14 days. The NTs+Wnt7a and NTs+lithium groups were treated with NTs for
the first 7 days and then with NTs+Wnt7a or lithium for the next 7 days. In inhibitory groups, SP600125 was added with Wnt7a or lithium in NT-
induced hMSCs at the same time. DAPI (blue) was used as a counterstain. DMEM groups were used as controls. The white bar represents 50 mm. (E)
Percentages of ChAT-positive cells and DBH-positive cells among all DAPI-positive cells calculated from (D). All data are presented as the mean 6 SD.
* p,0.05, ** p,0.01 (all vs. NTs).
# p,0.05,
## p,0.01 (all vs. NTs+Wnt7a+SP600125).
+ p,0.05,
++ p,0.01 (all vs. NTs+LiCl+SP600125). (F) As
described in "Materials and Methods", mRNA levels of ChAT and DBH were examined by a qPCR. Levels were normalized to those in NTs groups (set to
1.0). * p,0.05, ** p,0.01 (NTs+Wnt7a vs. all groups). (G) Percentages of inhibition calculated from (E). Data are presented as the mean 6 SD of one
triplicate experiment that was representative of three independent experiments.
doi:10.1371/journal.pone.0104937.g007
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neurotrophic factor treatment to mature. Recently, Yang et al.
used siRNA to NRSF/repressor element-1 silencing transcription
factors (REST) in hMSCs [42], and Park et al. used exogenous
Nurr1 gene delivery and electrical stimulation to induce the
differentiation of hMSCs into nerve cells [47]. These methods
induced rapid differentiation and caused hMSCs to develop a
neuron-like morphology, but synapse formation and neuronal
specification remained inadequately identified. From a clinical
perspective, gene manipulations are complex and unpredictable
regarding mature neuronal differentiation.
We noted Wnt7a was capable of enhancing neurogenic effect,
which was based on the effects of NTs. Only Wnt7a had no
neurogenic effects in hMSCs, although it activated signaling
pathway. Using Wnt7a siRNA may provide the information
whether NTs effects are originally from Wnt7a, and it does not
completely answer our question. Our goal is to identify the effect
of Wnt7a on NT-induced hMSCs, and is not to confirm
neurogenic effects of NTs. In our results, NTs directs hMSCs
toword the neuronal lineage, and NT-treated hMSCs can be
further triggered by Wnt7a to a mature neuronal differentiation.
Transdifferentiation into different germ layers is controversial in
developmental biology [48,49]. In early 2010, Vierbuchen et al.
demonstrated that functional neurons can be converted directly
from mouse fibroblasts through ectopic expression of 3 transcrip-
tion factors, Ascl1, Brn2, and Myt1l [50]. After mouse induced
neurons (iNs) were generated, several research groups generated
human iNs by using various sets of transcription factors in 2011
[51,52,53,54,55,56]. This new direct reprograming method
featuring defined factors indicates that transdifferentiation can
occur across germ layers. Transdifferentiation can be controlled
through epigenetic regulation and gene activation [57,58]. In
2012, Ladewig et al. reported that inhibiting GSK-3b and SMAD
signaling during reprogramming increased the efficiency of human
iN generation as well as the purity of the resulting iNs [59]. Our
results also supported the notion that the inhibition of GSK-3b
plays a crucial role in neurogenic transdifferentiation. Although no
molecular mechanisms of neurogenic transdifferentiation have
been identified, our data clearly indicate that hMSCs are capable
of neurogenic transdifferentiation.
Stem cell therapy is an alternative treatment for neural
degeneration because the loss of dopaminergic neurons is a major
cause of Parkinson’s disease [60]. Trzaska et al. demonstrated that
hMSCs differentiated into dopaminergic phenotypes following 12
days of incubation with Shh, FGF8, and bFGF [41]. In a
subsequent study, they observed that this system facilitates the
maturation of dopaminergic neurons after adding BDNF [61].
Our data revealed that Wnt7a can induce dopaminergic
differentiation in hMSCs. In future research, we will evaluate
the effects of combining Wnt7a with Shh and FGF to provide a
possible translational application for Parkinson’s disease.
Alzheimer’s disease is characterized by damage to the cholin-
ergic system of the basal forebrain [62], and the cholinergic
differentiation of MSCs is poorly understood. Previous studies
have reported that overexpression of the retinoblastoma family
gene, RB, triggers cholinergic phenotypes in hMSCs [63]. In
addition, one study reported that secreted amyloid precursor
protein-a (sAPPa) promoted cholinergic differentiation in mouse
MSCs [64]. Our study demonstrated that Wnt7a promotes
cholinergic differentiation in hMSCs. Thus, combining Wnt7a
with RB and sAPPa in hMSCs may enable cholinergic neurons to
be generated more efficiently, providing a potential therapy for
Alzheimer’s disease.
We demonstrated that Wnt7a promotes neuronal differentiation
and induces synapse formation and neuronal phenotype determi-
nation through b-catenin-dependent or -independent pathways
(Fig. 8). In conclusion, hrWnt7a enhances neuronal differentiation
and neurite formation in hMSCs through various Frz receptors.
These mechanisms may be employed widely in the transdiffer-
entiation of other adult stem cells.
Supporting Information
Figure S1 Controls of immunocytochemistry.
(TIF)
Figure S2 Dose-dependent and time-dependent effects
of GFAP and MBP expression in NT/Wnt7a-treated
hMSCs. Data are presented as the mean 6 SD of one triplicate
experiment that was representative of three independent experi-
ments. * p,0.05, ** p,0.01 (NTs and Wnt7a vs. DMEM; NTs+
Wnt7a vs. NTs).
(TIF)
Figure S3 Expression of GAD, SERT and GLUD1 in NT/
Wnt7a-treated hMSCs. All data are presented as the mean 6
SD. * p,0.05, ** p,0.01 (all vs. NTs).
(TIF)
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Figure 8. Summary of neuronal transdifferentiation regulation
by Wnt7a in human bone marrow-derived MSCs. Accompanying
NGF, BDNF, and RA, Wnt7a activated the canonical/b-catenin pathway
via receptor Frz5 to promote neurogenesis and trigger synaptic marker
(SYN1) expression. Furthermore, Wnt7a also triggered differentiations of
cholinergic and dopaminergic neurons, but this effect was induced by
another non-canonical/JNK pathway through Frz9 receptors. In this
study, we showed that Wnt7a utilized two pathways to promote hMSC
neurogenesis.
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